Hospital
Uintah Basin Medical Center
Uintah Basin Medical Center was paid $12.88M by Medicaid between Jan 2018 and Dec 2024, across 186 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.1% of everything it billed.
33Billing provider infoUINTAH BASIN MEDICAL CENTER
ROOSEVELT, UT 84066
ROOSEVELT, UT 84066
33aNPI1871556217assigned 04/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.88M
24GClaims302,519
24DCodes billed186
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#8 of 26
Median peer was paid$6.14M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,363 | $981K | |
| 2019 | 40,959 | $1.19M | |
| 2020 | 51,546 | $2.11M | |
| 2021 | 64,650 | $2.86M | |
| 2022 | 56,921 | $2.36M | |
| 2023 | 31,570 | $1.88M | |
| 2024incomplete | 20,510 | $1.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 15,713 | 14,244 | $1.17M |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 8.8% | 4,930 | 3,987 | $1.13M |
| 36415 | Collection of venous blood by venipuncture | 6.7% | 27,421 | 22,187 | $868K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.2% | 10,454 | 9,020 | $801K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 4.4% | 362 | 295 | $568K |
| 8888888 | Internal/system code - not a standard HCPCS code | 4.1% | 4,875 | 1,309 | $534K |
| J7050 | Infusion, normal saline solution, 250 cc | 3.4% | 1,866 | 1,185 | $434K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 5,108 | 4,468 | $411K |
| J2704 | Injection, propofol, 10 mg | 3.1% | 1,985 | 1,656 | $396K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 2.7% | 787 | 628 | $348K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2.4% | 2,493 | 2,102 | $314K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2.4% | 2,199 | 1,733 | $309K |
174 more codes
| J7030 | Infusion, normal saline solution , 1000 cc | 2.3% | 7,671 | $295K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.3% | 2,210 | $294K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 5,677 | $251K |
| 87631 | 1.8% | 2,700 | $238K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.8% | 1,993 | $227K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 3,254 | $224K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 1.4% | 575 | $182K |
| 80050 | General health panel | 1.4% | 3,272 | $178K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1.2% | 1,588 | $161K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.2% | 1,648 | $160K |
| J2550 | Injection, promethazine hcl, up to 50 mg | 1.2% | 666 | $151K |
| A0425 | Ground mileage, per statute mile | 1.1% | 805 | $143K |
| A0429 | Emergency ambulance ride, basic life support | 1.1% | 261 | $143K |
| J3490 | Unclassified drugs | 1.1% | 422 | $142K |
| 81001 | 1.1% | 16,614 | $136K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 3,541 | $134K |
| 84703 | <1% | 2,928 | $100K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,902 | $96K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 946 | $94K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 804 | $92K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,333 | $92K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,281 | $90K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,712 | $87K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,159 | $85K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,131 | $84K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 289 | $83K |
| 87088 | <1% | 5,463 | $81K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 825 | $77K |
| 80053 | Comprehensive metabolic panel | <1% | 15,187 | $76K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,603 | $72K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,110 | $71K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,810 | $65K |
| 73630 | <1% | 1,207 | $56K | |
| 59025 | Fetal non-stress test | <1% | 2,811 | $54K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,376 | $54K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 458 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,335 | $45K |
| 73610 | <1% | 1,052 | $44K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,309 | $42K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,390 | $40K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 327 | $39K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,275 | $39K |
| 73130 | <1% | 1,164 | $36K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 450 | $33K |
| 73562 | <1% | 752 | $29K | |
| 72100 | <1% | 746 | $29K | |
| 88142 | <1% | 1,353 | $28K | |
| 97161 | <1% | 286 | $27K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 314 | $26K |
| 73110 | <1% | 558 | $24K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 442 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,265 | $20K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 68 | $19K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,648 | $18K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 340 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,844 | $17K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 250 | $17K |
| 82948 | <1% | 1,738 | $17K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,645 | $16K |
| 73030 | <1% | 489 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,263 | $15K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 69 | $14K |
| 85651 | <1% | 1,542 | $14K | |
| 99223 | Prolong inpt eval add15 m | <1% | 104 | $13K |
| 83690 | <1% | 4,560 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 66 | $12K |
| 83605 | <1% | 5,231 | $11K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 122 | $11K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 511 | $11K |
| 83516 | <1% | 596 | $10K | |
| 87070 | <1% | 1,213 | $10K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 165 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,334 | $9K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 300 | $8K |
| 87590 | <1% | 738 | $8K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 102 | $7K |
| 87490 | <1% | 737 | $7K | |
| 84484 | <1% | 2,090 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 41 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 115 | $7K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 15 | $6K |
| 87040 | <1% | 1,728 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,526 | $6K |
| A4550 | Surgical trays | <1% | 123 | $5K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 3,453 | $5K |
| 73140 | <1% | 90 | $5K | |
| 74018 | <1% | 109 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 766 | $5K |
| 86803 | <1% | 58 | $5K | |
| 87653 | <1% | 687 | $5K | |
| 83880 | <1% | 757 | $4K | |
| 62323 | <1% | 12 | $4K | |
| 83540 | <1% | 510 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 685 | $3K |
| 73564 | <1% | 71 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 627 | $3K |
| 94762 | <1% | 19 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,694 | $2K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 71 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 25 | $2K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 26 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,717 | $2K |
| A6219 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 87 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 123 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 39 | $2K |
| 73080 | <1% | 14 | $2K | |
| 86140 | <1% | 1,377 | $1K | |
| 88342 | <1% | 17 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 41 | $1K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 16 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,231 | $898.10 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 18 | $877.30 |
| 85610 | <1% | 1,214 | $795.96 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 13 | $713.25 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 111 | $646.79 |
| 86592 | <1% | 1,025 | $594.69 | |
| 99152 | <1% | 43 | $575.99 | |
| 84702 | <1% | 948 | $523.09 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13 | $429.17 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 614 | $396.70 |
| 80061 | Lipid panel | <1% | 2,312 | $382.86 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,623 | $354.57 |
| 86769 | <1% | 35 | $300.92 | |
| 84550 | <1% | 64 | $293.77 | |
| 86703 | <1% | 1,300 | $254.54 | |
| 84481 | <1% | 596 | $251.76 | |
| 93971 | <1% | 16 | $251.16 | |
| 73502 | <1% | 25 | $206.95 | |
| 84439 | <1% | 2,385 | $195.23 | |
| 73100 | <1% | 25 | $166.20 | |
| 84403 | <1% | 44 | $151.52 | |
| 82043 | <1% | 132 | $129.98 | |
| 83735 | <1% | 973 | $122.97 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $112.99 |
| 85378 | <1% | 690 | $108.99 | |
| 86901 | <1% | 1,200 | $103.53 | |
| 82550 | <1% | 499 | $102.84 | |
| 84460 | <1% | 224 | $62.86 | |
| 87045 | <1% | 84 | $59.34 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $35.09 |
| 87177 | <1% | 14 | $23.98 | |
| 87340 | <1% | 624 | $13.18 | |
| 82607 | <1% | 535 | $10.28 | |
| 82950 | <1% | 526 | $6.48 | |
| 82565 | <1% | 142 | $5.12 | |
| 86900 | 0% | 897 | $0.00 | |
| 80074 | 0% | 261 | $0.00 | |
| 84450 | 0% | 214 | $0.00 | |
| 84520 | 0% | 117 | $0.00 | |
| 86431 | 0% | 41 | $0.00 | |
| A6530 | Gradient compression stocking, below knee, 18-30 mmhg, each | 0% | 129 | $0.00 |
| 83970 | 0% | 20 | $0.00 | |
| 88312 | 0% | 16 | $0.00 | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 12 | $0.00 |
| 83525 | 0% | 19 | $0.00 | |
| 86038 | 0% | 23 | $0.00 | |
| 82728 | 0% | 536 | $0.00 | |
| 82553 | 0% | 142 | $0.00 | |
| 81511 | 0% | 81 | $0.00 | |
| 86850 | 0% | 836 | $0.00 | |
| 86762 | 0% | 347 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 25 | $0.00 |
| 85730 | 0% | 289 | $0.00 | |
| 82150 | 0% | 14 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 53 | $0.00 |
| 83001 | 0% | 68 | $0.00 | |
| 82784 | 0% | 26 | $0.00 | |
| 86812 | 0% | 13 | $0.00 | |
| 83550 | 0% | 30 | $0.00 | |
| 83002 | 0% | 18 | $0.00 | |
| 84153 | 0% | 57 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 22 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSHALL, JAMES (CEO/PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Uintah Basin Medical Center | Roosevelt, UT | $6.89M |
| Uintah Basin Medical Center | Roosevelt, UT | $3.14M |
| Uintah Basin Medical Center | Vernal, UT | $429K |
| Pemiscot County Memorial Hospital | Steele, MO | $328K |
| Pemiscot County Memorial Hospital | Gideon, MO | $290K |
| Uintah Basin Medical Center | Duchesne, UT | $180K |
| Uintah Basin Medical Center | Roosevelt, UT | $158K |
| Uintah Basin Medical Center | Vernal, UT | $47K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.